Science and Research

Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent first-line standard of care in unresectable EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC). However, 10-20% of patients with EGFRm+ NSCLC have uncommon EGFR variants, defined as mutations other than L858R substitutions or exon 19 deletions. NSCLC harboring uncommon EGFR mutations may demonstrate lower sensitivity to targeted agents than NSCLC with L858R or exon 19 deletion mutations. Prospective clinical trial data in patients with NSCLC uncommon EGFR mutations are lacking. Afatinib is a second-generation TKI and the only Food and Drug Administration-approved drug for some of the more prevalent uncommon EGFR mutations. We present a series of seven case reports describing clinical outcomes in afatinib-treated patients with NSCLC harboring a diverse range of extremely rare mutations with or without co-mutations affecting other genes. EGFR alterations included compound mutations, P-loop

  • Christopoulos, P.
  • Herster, F.
  • Hoffknecht, P.
  • Falk, M.
  • Tiemann, M.
  • Kopp, H. G.
  • Althoff, A.
  • Stammberger, A.
  • Laack, E.

Keywords

  • Egfr
  • afatinib
  • non-small cell lung cancer (NSCLC)
  • tyrosine kinase inhibitor
  • uncommon mutation
Publication details
DOI: 10.3389/fonc.2024.1347742
Journal: Front Oncol
Pages: 1347742 
Work Type: Original
Location: TLRC
Disease Area: LC
Partner / Member: Thorax
Access-Number: 38769948

DZL Engagements

chevron-down